ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
Last trade$70.06
Day change-$0.83 (-1.17%)
Day range$69.98 – $70.95
Volume86,049
Market cap$1.61B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.61B
Price / earnings
14.85×
Price / book
2.53×
Price / sales
1.55×
EV / sales
1.73×
EV / EBITDA
7.21×
Profitability
Earnings per share
$4.78
Return on assets
6.92%
Return on equity
17.04%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.95×
Current ratio
2.75×
Quick ratio
2.33×
Cash ratio
1.28×
Cash flow
Price / cash flow
7.03×
Price / free cash flow
7.85×
Free cash flow
$205.32M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ANIP, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$290.78M
$266.04M
$237.46M
$247.06M
$227.81M
$211.37M
$197.12M
$190.57M
Cost of revenue
$111.53M
$100.16M
$93.58M
$100.27M
$93.39M
$74.62M
$73.04M
$80.28M
Gross profit
$179.25M
$165.89M
$143.88M
$146.79M
$134.42M
$136.76M
$124.09M
$110.29M
Selling, general and administrative
$94.86M
$91.66M
$73.66M
$82.79M
$76.66M
$81.77M
$76.53M
$69.72M
Research and development
$13M
$14.75M
$10.6M
$12.26M
$12.3M
$16.54M
$10.56M
$16.65M
Total operating expenses
$126.87M
$125.43M
$104.99M
$111.94M
$97.89M
$122.86M
$97.89M
$114.67M
Operating income
$52.37M
$40.46M
$38.89M
$34.85M
$36.54M
$13.89M
$26.19M
-$4.38M
Interest expense
-$3.06M
-$3.64M
$0
-$20.06M
-$4.73M
-$5.44M
$0
-$17.6M
Income before taxes
$49.04M
$37.1M
$40.22M
$31.48M
$33.8M
$10.53M
$19.99M
-$13.76M
Income taxes
$13.89M
$12.39M
$10.73M
$3.99M
$7.18M
$1.98M
$4.31M
-$3.49M
Net income
$35.15M
$24.71M
$29.49M
$27.49M
$26.62M
$8.55M
$15.68M
-$10.28M
Net income attributable to common shareholders
$32.72M
$23M
$27.43M
$25.39M
$23.79M
$7.32M
$13.71M
-$10.68M
EBITDA
$71.93M
$60.1M
$59.81M
$57.47M
$59.93M
$37.17M
$49.09M
$25.82M
Basic earnings per share
$1.54
$1.09
$1.31
$1.23
$1.19
$0.37
$0.70
-$0.55
Diluted earnings per share
$1.51
$1.05
$1.28
$1.08
$1.13
$0.36
$0.69
-$0.56
Recent news
Company coverage with links to the original publishers.
The second annual Global Health Congress convened 625+ healthcare leaders from 25+ countries at the Yale Club of New York City (October 9-11, 2026). The Healthcare Shark Tank competition received 350+ startup applications from 35+ countries, with four winners announced: Stabilis Medical, Florence, Wink, and Braiv. Global Health Forum announced expansion plans for regional chapters across the United States and internationally in India, the United Kingdom, and the Middle East.
ANI Pharmaceuticals (ANIP) is highlighted as a stock with strong potential to beat upcoming earnings estimates. The company has demonstrated a consistent track record of earnings surprises, with an average surprise of 35.05% over the past two quarters. With a positive Earnings ESP of +6.45% and a Zacks Rank #3 (Hold), the stock shows indicators suggesting another earnings beat is likely.
The article highlights two medical stocks with positive Earnings Surprise Prediction (ESP) metrics that could beat their upcoming quarterly earnings estimates. ANI Pharmaceuticals (ANIP) has a +6.45% ESP ahead of its November 6, 2026 earnings release, while Regeneron (REGN) has a +0.23% ESP before reporting on October 30, 2026. Both stocks carry a Zacks Rank #3 (Hold) rating, and the article suggests that stocks with positive ESP combined with a Zacks Rank #3 or better have historically beaten earnings 70% of the time.
The article explains how to identify medical stocks poised for earnings surprises using the Zacks Earnings ESP (Expected Surprise Prediction) tool. It highlights that combining a positive ESP with a Zacks Rank #3 or better has historically produced 70% positive surprises and 28.3% average annual returns. Two medical stocks are featured as examples: Solventum (SOLV) with a +2.81% ESP and ANI Pharmaceuticals (ANIP) with a +6.45% ESP, both expected to report earnings in early November 2026.
ANI Pharmaceuticals announced it will release its second quarter 2026 financial results on August 7, 2026, with executives hosting a webcast and conference call. The company also announced positive six-month topline data from its Phase 4 SYNCHRONICITY trial evaluating fluocinolone acetonide intravitreal implant for chronic non-infectious uveitis, meeting both co-primary endpoints.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.